Literature DB >> 21939268

Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.

Kathryn E Pietsch1, James F Neels, Xiang Yu, Jiachang Gong, Shana J Sturla.   

Abstract

Acylfulvenes (AFs), a class of semisynthetic analogues of the sesquiterpene natural product illudin S, are cytotoxic toward cancer cells. The minor structural changes between illudin S and AFs translate to an improved therapeutic window in preclinical cell-based assays and xenograft models. AFs are, therefore, unique tools for addressing the chemical and biochemical basis of cytotoxic selectivity. AFs elicit cytotoxic responses by alkylation of biological targets, including DNA. While AFs are capable of direct alkylation, cytosolic reductive bioactivation to an electrophilic intermediate is correlated with enhanced cytotoxicity. Data obtained in this study illustrate chemical aspects of the process of AF activation. By tracking reaction mechanisms with stable isotope-labeled reagents, enzymatic versus chemical activation pathways for AF were compared for reactions involving the NADPH-dependent enzyme prostaglandin reductase 1 (PTGR1) or sodium borohydride, respectively. These two processes resulted in isomeric products that appear to give rise to similar patterns of DNA modification. The chemically activated isomer has been newly isolated and chemically characterized in this study, including an assessment of its relative stereochemistry and stability at varying pH and under bioassay conditions. In mammalian cancer cells, this chemically activated analogue was shown to not rely on further cellular activation to significantly enhance cytotoxic potency, in contrast to the requirements of AF. On the basis of this study, we anticipate that the chemically activated form of AF will serve as a useful chemical probe for evaluating biomolecular interactions independent of enzyme-mediated activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939268      PMCID: PMC3236363          DOI: 10.1021/tx200401u

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  32 in total

1.  FUNGAL METABOLITES. THE STRUCTURES OF THE NOVEL SESQUITERPENOIDS ILLUDIN-S AND -M.

Authors:  T C MCMORRIS; M ANCHEL
Journal:  J Am Chem Soc       Date:  1965-04-05       Impact factor: 15.419

Review 2.  Anticancer active illudins: recent developments of a potent alkylating compound class.

Authors:  R Schobert; S Knauer; S Seibt; B Biersack
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Production of Illudin M and of a Fourth Crystalline Compound by Clitocybe Illudens.

Authors:  M Anchel; A Hervey; W J Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  1952-11       Impact factor: 11.205

4.  Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent.

Authors:  Jiachang Gong; V G Vaidyanathan; Xiang Yu; Thomas W Kensler; Lisa A Peterson; Shana J Sturla
Journal:  J Am Chem Soc       Date:  2007-01-27       Impact factor: 15.419

5.  Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).

Authors:  J M Woynarowski; C Napier; S K Koester; S F Chen; D Troyer; W Chapman; J R MacDonald
Journal:  Biochem Pharmacol       Date:  1997-12-01       Impact factor: 5.858

6.  Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct.

Authors:  M Tomasz; D Chowdary; R Lipman; S Shimotakahara; D Veiro; V Walker; G L Verdine
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

7.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.

Authors:  T C McMorris; M J Kelner; W Wang; J Yu; L A Estes; R Taetle
Journal:  J Nat Prod       Date:  1996-09       Impact factor: 4.050

8.  Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.

Authors:  T C McMorris; A N Elayadi; J Yu; Y Hu; M J Kelner
Journal:  Drug Metab Dispos       Date:  1999-09       Impact factor: 3.922

9.  Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.

Authors:  Jiachang Gong; James F Neels; Xiang Yu; Thomas W Kensler; Lisa A Peterson; Shana J Sturla
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

10.  NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.

Authors:  Ryan A Dick; Xiang Yu; Thomas W Kensler
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

View more
  5 in total

1.  Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.

Authors:  Paul M van Midwoud; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2013-11-05       Impact factor: 3.739

2.  Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities.

Authors:  Kathryn E Pietsch; Paul M van Midwoud; Peter W Villalta; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2012-12-19       Impact factor: 3.739

3.  RFWD3 and translesion DNA polymerases contribute to PCNA modification-dependent DNA damage tolerance.

Authors:  Rie Kanao; Hidehiko Kawai; Toshiyasu Taniguchi; Minoru Takata; Chikahide Masutani
Journal:  Life Sci Alliance       Date:  2022-07-29

4.  Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.

Authors:  Melanie M Erzinger; Cédric Bovet; Katrin M Hecht; Sabine Senger; Pascale Winiker; Nadine Sobotzki; Simona Cristea; Niko Beerenwinkel; Jerry W Shay; Giancarlo Marra; Bernd Wollscheid; Shana J Sturla
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

5.  High Expression of PTGR1 Promotes NSCLC Cell Growth via Positive Regulation of Cyclin-Dependent Protein Kinase Complex.

Authors:  Xianping Huang; Weihe Zhou; Yuefeng Zhang; Yong Liu
Journal:  Biomed Res Int       Date:  2016-06-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.